Dec 9 (Reuters) - United Therapeutics Corp said itreceived a subpoena from the U.S. Department of Health and HumanServices regarding marketing practices used to sell three of itsdrugs to treat pulmonary arterial hypertension (PAH).
The subpoena, which follows an investigation by theDepartment of Justice, requires the company to submit documentsregarding its Remodulin injection, Tyvaso inhalation solutionand Adcirca tablets, the company said on Monday.
These three drugs are the only treatments for which UnitedTherapeutics holds marketing approval from the U.S. Food andDrug Administration, according to the company's website.
PAH is increased pressure in the arteries of the lungs.These arteries carry blood from the heart to the lungs to pickup oxygen.
The company said it planned to cooperate with theinvestigation.
Shares of the Silver Spring, Maryland-based company closedat $90.97 on the Nasdaq on Friday.
- Health Care Industry
- United Therapeutics